2seventy bio Q4 2023 Earnings Call Transcript

Quartr
Provided by Quartr
March 5, 2024

There are 7 speakers on the call.

Operator

Good day and thank you for standing by. Welcome to the 270 Bio 4th Quarter 2023 Earnings Conference Call. At this time, all participants

Speaker 1

are in

Operator

a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Elizabeth Hicken, Head of Investor Relations. Please go ahead.

Speaker 2

Thank you, operator, and good morning, everyone. Thank you for joining us. This morning, we issued a press release on our Q4 and full year 2023 financial results. The press release can be found in the Investors and Media section of company's website at 270bio.com. As a reminder, today's discussion will include forward looking statements related to 270 Bio's current plans and expectations, which are subject to certain risks and uncertainties.

Speaker 2

These forward looking statements include statements regarding our strategic plans, timelines and expectations with respect to sales, efficacy and perceived therapeutic benefits of Abekma, the timing and review of additional studies and regulatory applications for Abekma and statements regarding our financial condition, expectations and future financial results among others. Actual results may differ materially due to various risks, uncertainties and other factors, including those described in the Risk Factors section of our most recent Form 10 ks, quarterly reports and other SEC filings. These forward looking statements represent our views as of this call and should not be relied upon as representing our views as of any subsequent date. You are cautioned not to place any undue reliance on these forward looking statements and except as required by law, we undertake no obligation to update or revise any forward looking statements. On today's call, we are joined by Chip Baird, Incoming's Chief Executive Officer and Vicki Eatwell, Incoming's Chief Financial Officer.

Speaker 2

Anna Treppel Hartman, Head of Clinical Development is also on the line for Q and A. And now, I will turn it over to Chip. Chip?

Speaker 1

Thank you, Liz, and thank you all for joining. This morning, we disclosed our Q4 and full year 2023 financial results and recent business and operational updates. I'd like to walk through some of the business updates and then Vicki Ewell, our incoming Chief Financial Officer will go into detail on the financials. First, as we announced in January, we have embarked on a new strategic path forward as an organization that will be wholly focused on Abeka. As part of this new path forward, we entered into an asset purchase agreement with Regeneron to acquire our research and development pipeline.

Speaker 1

I'm pleased to share that we've made good progress on the agreement and continue to believe we are on track to close within the first half of the year. Turning to abecma, we're looking forward to discussing our SBLA in the third line at the upcoming ODAC meeting next week. As we've shared, FDA has said they are focused on the overall survival data from the Karma-three study, which was presented at ASH and importantly showed a benefit in the abacma arm when adjusted for crossover. We believe these data support the case to prove abacma in this triple class exposed patient population. We're pleased to see regulators across other geographies respond positively with 3rd line plus approvals in Japan and Switzerland as well as a positive CHMP opinion in the EU, which gives us confidence in a potential approval here in the U.

Speaker 1

S. Our clinical and regulatory our clinical and regulatory teams at 270 and at BMS have been diligent and thorough in our preparation for the ODAC and we look forward to the meeting next week. From a commercial perspective, the approval in the 3rd line plus setting is a key catalyst for Beqra returning to return to growth. To that end, we and BMS are prepared to meet the anticipated demand in earlier lines and importantly to continue to deliver Abekma on time and in spec for patients in need. These efforts are in addition to other ongoing efforts to expand site footprint and competitively differentiate Beqma safety and efficacy profile with real world data.

Speaker 1

We look forward to educating the communities together with BMS on these data and we remain excited about the potential for Beqma to transform the lives of patients living with myeloma. With these efforts and our extended cash runway, we believe 270 is strongly positioned to see Beqma return to growth this year and deliver for patients in need. Before I close, I'd like to turn the call to Vicki to walk through some of our financials. Vicki, over to you.

Speaker 3

Thanks, Chip. As mentioned, 4th quarter Abekma U. S. Revenues as reported by Bristol Myers Squibb were $56,000,000 The decline in 4th quarter sales was due to ongoing competition from other BCMA targeted therapies. We anticipate the commercial performance for the 1st part of 2024 will continue to be impacted by competitive dynamics until the potential expansion at the label to the 3rd line plus setting, which will increase the addressable patient population.

Speaker 3

In the 4th quarter, 270 Bio reported collaborative arrangement revenue of $2,000,000 related to its collaboration with BMS for the 3 months ended December 31, 2023 and collaborative arrangement revenue of $50,000,000 related to its collaboration with BMS for the 12 months ended December 31, 2023. We anticipate collaborative arrangement revenue to grow meaningfully as we see Avecma return to commercial growth. We ended the year with 221,800,000 of cash, cash equivalents and marketable securities. With the changes to the cost structure resulting from restructuring measures and following the close of the asset purchase agreement with Regeneron, we expect annual savings of approximately $150,000,000 in 2024 and approximately $200,000,000 in 2025, inclusive of one time cash restructuring costs of approximately $8,000,000 to $10,000,000 We now expect our cash runway to go beyond 2027 and see a path to potential breakeven by 2025, obviating the need to seek funding from the capital markets in the foreseeable future. With that, I'll turn it back to Chip.

Speaker 1

Thanks, Vicki. Before we close, I'd like to thank the team at 270 for continuing to navigate these challenging waters and not losing sight of the mission and the clear task at hand. With key milestones coming in the near term, close of the APA with Regeneron, ODAC and PDUFA soon thereafter, we feel we are well positioned to emerge from the Q1 in a much stronger position. We look forward to continuing to support our partners at BMS as they bring it back to myeloma patients in need. With that, we're happy to take your questions.

Speaker 1

Operator, over to you.

Operator

Thank Our first question comes from the line of Dana Graybosch with Leerink Partners. Your line is now open.

Speaker 4

Yes. I'd like to ask a question about toxicity profile. Think you've often spoken in the past that the lack of delayed neurotoxicity, whether the more severe or the less severe forms of that are a potential advantage. But you're still not necessarily seeing that in the revenue numbers. And I can wonder how your conversations with doctors in the field are going and whether you expect toxicity to be a major point of discussion at the ODAC?

Speaker 1

Thanks, Dana. It's a good question and that's one that's been known and on the label for some time. I would comment broadly at a commercial perspective that the tox profile becomes increasingly important as we move towards earlier line settings when there are other treatment options available and when the kind of benefit risk profile just is inherently different. So I think that will be an important factor as we move into this 3rd line plus setting. But we'll turn it to Anna to comment from a clinical perspective and MD perspective.

Speaker 5

Anna? Thank you, Chip, and thank you, Dana. It is also important to note that Riverd experience is growing as well in the field, which also has an impact on to you. So with all the revert evidence that has been published in the last month or so at last, there was a VALC data. We can see that there is lots of delayed neurotoxicity such as parkinsonism for some other products, not as much for Abekma.

Speaker 5

And I think these kind of data will also influence how treaters see the toxicity profile for the product.

Operator

Thank you. Our next question comes from the line of Salveen Richter with Goldman Sachs. Your line is now open.

Speaker 3

Hi, this is Lydia on for Salveen. Thanks so much for taking our question. Just on the upcoming ODAC meeting, what key piece of data do you think best supports the overall survival data? Thanks so much.

Speaker 1

Yes. Ana, do you want to comment on that one?

Speaker 5

Yes. Thank you very much for the question. So the overall survival data has a key confounding factor, which is the crossover. We have used a very patient centric study design And therefore, we haven't seen a difference between the center of care of an abeka mine in the overall survival. But when adjusting for crossover, as mentioned by Chip before, then it really seems to favor abecma.

Speaker 5

So this is kind of an important point when looking at overall survival data. In addition to that, we have had discussions around bridging therapies as well for the ITT population. And due to the impact of bridging therapies and the importance of bridging therapies, we've seen some imbalance in the early part of couple of microbes, but overall survival seems to be really favoring Ide cel when adjusting for the crossover. Yes.

Speaker 1

And the only thing I'd add there is overall survival was a focus of, as we said before, the regulatory discussions in Japan and in Europe and Swiss regulatory authorities. So this is a topic that we've had experience talking to regulators about. The team has been diligent in the prep for the meeting. And so we look forward to discussions next Friday.

Operator

Thank you. Our next question comes from the line of Yaron Werber with TD Cowen. Your line is now open.

Speaker 6

Hi, this is Jaina on for Yaron. Thanks for taking our question. You're already facing a lot of competition from CARVERICKI and bispecifics. But looking further ahead, do you think that ADECMOS lead to market is going to be sufficient to be competitive even with newer CAR Ts in development like Arcellus and Gilead's needle cell or Novartis' C885? Or do you think demand is going to be increasing enough as CAR Ts and Web Stream to make room for several CAR Ts to coexist?

Speaker 1

Yes. Thanks for the question. I think the history of myeloma has always been never a winner take all scenario. This is a huge market. It's a complex market.

Speaker 1

Patients progress through different lines of therapies in a myriad of different ways. And again, as we expand from the current label to this expanded third line plus setting, the market opportunity is significant, will be difficult for any one manufacturer to meet that demand. And as Anna alluded to before, as we look at the real world evidence and as we understand more and more about these therapies, not outside the strict confines and controlled setting of a clinical study, but actually in their use and application in the real world, differences emerge And our understanding of what's the best product for the best patient population evolves. And we think that's going to play out over a very long time. I think the outside world has taken somewhat of a winner take all kind of mindset and that's convenient and that's a but we think it's a simple it's an oversimplification of the nuance between these different products.

Speaker 1

The the benefit risk profile, BevecMo, we like the safety and efficacy profile. We think it's competitive and we look forward to educating on that in the Foteline Plus setting throughout the balance of this year.

Operator

Thank you. Our next question comes from the line of Kelsey Goodwin with Guggenheim Securities. Your line is now open.

Speaker 3

Hey, good morning. Thank you for taking my question. I guess on the real world evidence that's being generated, could you just remind us what are the major key areas of differentiation for Avecma that's arising with the real world data? And then maybe quickly a follow-up on increasing the site footprint. Could you maybe just expand a bit there?

Speaker 3

I guess, are these sites that already have existing CAR T infrastructure? And how will that build outlook? Thank you so much.

Speaker 1

Sure. Thanks, Kelsey. Maybe I'll take the site footprint question first and then we can talk about the point of differentiation that are emerging in the real world evidence and real world setting. From a site footprint perspective, we've as we've described before, we continue to increase the number of sites where Beqima is available for patients in a large market like the U. S.

Speaker 1

That's really important for patients, particularly later line patients for whom extended travel is difficult. So again, we started in larger cities and larger academic centers, where the catchment was just larger and that made a lot of sense. But as we've increased the footprint, that's going to make Beqima available for more and more patients. And we have plans to continue to expand that footprint over time. So that's an important commercial driver, but I think the main one is going to be our ability to describe and articulate both the safety profile and the efficacy the competitive efficacy profile of Opecma in the 30 9 plus setting.

Speaker 1

In terms of the what we're seeing and some of those competitive differentiators in the real world evidence, again, it's both safety, and I think a closing of the gap from the efficacy perspective. But Ana, I think would be best to comment on that.

Speaker 5

Yes. Thank you, Chip. The VIVOR evidence data is wonderful to see that the bulk of data is increasing with Abeka being available now for a while commercially. And what we really can see is that we whatever data set that is looked at in the data are reproducible from the CARMA pivotal study. So any data set has shown either the same efficacy or even better efficacy.

Speaker 5

And of note, many of those patients that are treated in VIRBOT wouldn't have been eligible for the pivotal study. So this is very encouraging to see that the VIRVOR DEVINENCE data seem to be very beneficial for Abekma with regards to efficacy, but also with regards to safety. I do think there was also a lot of data around safety profile of the new agents approved in myeloma and also there, Abekma looks very good compared to the other profiles with regards to non relapsed mortality or infections or delayed neurotoxicities, etcetera. So I do think we are very pleased to see how the body of evidence in real world is showing positive

Operator

results. Thank you. Our next question comes from the line of Samantha Simcoe with Citi. Your line is now open.

Speaker 6

Hi, good morning. Thanks for taking our question. I'm wondering if you're able to share any insights on Avecho's utilization trends over the last several months or quarters. What types of patients are receiving, continuing to receive Avecma? How are physicians making the decisions to utilize the bekma versus their competitive BCMA options?

Speaker 6

What types of centers are you seeing bekma use? Any insight you're able to provide would be helpful. Thank you.

Speaker 1

Hi, Sam. Yes, thanks for the question. I would say it's really site specific in terms of how it's being used. So again, we don't tend to think of Bebekma being niched for a given type of patients. So really, I think it depends on the site in terms of whether it's an IMBECMA only site, whether it's an IMBECMA and T cell engager site or whether they have multiple CAR Ts.

Speaker 1

Those are all different factors that I think impact how Beccma is being deployed. But certainly as we think about both the 5th line and looking forward to the 3rd line plus setting, we don't see abacma as a niche to a given subset of patients. But Anna, anything from a clinical perspective to add?

Speaker 5

No, thanks. Thank you.

Operator

Thank you. I'm showing no further questions at this time. I'd like to hand the call back over to Chip Baird for closing remarks.

Speaker 1

Thank you everyone for making time for the call today. We look forward to sharing more updates and I'm sure we'll be talking again on the other side of the ODEC meeting this week. And with that, wish everyone a great day. Thank you.

Operator

This concludes today's conference call. Thank you for your participation. You may now disconnect.

Powered by Quartr

Key Takeaways

  • 270 Bio has pivoted to focus solely on Abecma and is on track to close an asset purchase agreement with Regeneron to acquire its R&D pipeline in H1 2024.
  • The company is preparing for next week’s ODAC meeting on its third-line supplemental BLA for Abecma, supported by overall survival data from the KarMMa-3 study (adjusted for crossover) and recent positive regulatory opinions in Japan, Switzerland and the EU.
  • 270 Bio and BMS are ready to scale commercial operations—expanding the site footprint, leveraging real-world data to highlight Abecma’s safety and efficacy profile, and meeting anticipated demand in the third-line plus setting.
  • In Q4 2023, Abecma US sales were $56 million (down due to competitive dynamics) and 270 Bio reported $2 million in collaborative revenue for the quarter ($50 million for the full year), ending the year with $221.8 million in cash and marketable securities.
  • Following restructuring measures expected to save ~$150 million in 2024 and ~$200 million in 2025 (with one-time costs of $8–10 million), the company now has a cash runway beyond 2027 and anticipates reaching breakeven by 2025 without further capital raises.
AI Generated. May Contain Errors.
Earnings Conference Call
2seventy bio Q4 2023
00:00 / 00:00